Posted by Michael Wonder on 17 Feb 2023
Chiesi Global Rare Diseases announces FDA approval of Lamzede (velmanase alfa-tycv) for alfa mannosidosis
16 February 2023 - First and only enzyme replacement therapy for the treatment of non-central nervous system manifestations of alfa mannosidosis in adult and paediatric patients.
Chiesi Global Rare Diseases announced today that the US FDA has approved Lamzede (velmanase alfa-tycv) for the treatment of non-central nervous system manifestations of alfa mannosidosis in adult and paediatric patients.
